Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06671119 · ClinicalTrials.gov registry record · NA

REvision of VSG with Ablation of the Mucosa Procedure

A NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, sponsored by Dr. Christopher McGowan.

Recruiting
Registry status
NA
Development phase
5
Enrollment target
1
Study location

NCT06671119: Recruiting NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, sponsored by Dr. Christopher McGowan.

NCT06671119 is a NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions that is actively recruiting participants, run by Dr. Christopher McGowan. The registered enrollment target is 5 participants, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06671119, a NA study of Obesity and Overweight and Obesity and Obesity-related Medical Conditions, is actively recruiting participants, sponsored by Dr. Christopher McGowan.

RECRUITING
Registry status
NA
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the feasibility, safety, and tolerability of endoscopic selective gastric mucosal ablation (GMA) using argon plasma coagulation after sleeve gastrectomy. In this study, GMA will be performed on patients who have experienced weight regain following an initial successful response to sleeve gastrectomy.

Primary Outcome

Measure percent change in total body weight over time following endoscopic GMA. TBWL = pre-op weight - post op body weight. % TBWL is the fraction of body weight expressed in percentage term

Conditions Studied

Obesity and Overweight Obesity and Obesity-related Medical Conditions Obesity Prevention Obesity Recidivism

Interventions

  • DEVICE Gastric Mucosal Ablation (GMA)

Study Locations (1)

North Carolina

  • True You Weight Loss - Cary

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2024-12
Est. Completion 2026-05
Phase NA
Dr. Christopher McGowan

2 total trials

What NCT06671119 shows while recruiting

NCT06671119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Obesity and Overweight appearing as the primary indexed condition, and to 1 intervention - of which Gastric Mucosal Ablation (GMA) is the first listed.

NCT06671119 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06671119 about?

NCT06671119 is a clinical study titled "REvision of VSG with Ablation of the Mucosa Procedure". The purpose of this study is to evaluate the feasibility, safety, and tolerability of endoscopic selective gastric mucosal ablation (GMA) using argon plasma coagulation after sleeve gastrectomy. In this study, GMA will be performed on patients who have experienced weight regain following an initial ...

What is the current status of trial NCT06671119?

This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2024-12. Estimated completion is 2026-05.

What conditions does trial NCT06671119 study?

This clinical trial studies the following conditions: Obesity and Overweight, Obesity and Obesity-related Medical Conditions, Obesity Prevention, Obesity Recidivism.

What interventions are being tested in trial NCT06671119?

The interventions under investigation include: Gastric Mucosal Ablation (GMA) (DEVICE).

Who is sponsoring clinical trial NCT06671119?

This trial is sponsored by Dr. Christopher McGowan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06671119 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06671119's enrollment target sits among peer trials

5 28th of 27 the lowest of 27 other Obesity and Overweight trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT06671119

Source: ClinicalTrials.gov NCT06671119, the US trial registry maintained by the National Library of Medicine. NCT06671119 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.